• Editor

WHO scientist Soumya Swaminathan served for spreading disinformation on COVID-19 and Ivermectin


Indian paediatrician and WHO clinical scientist, Dr Soumya Swaminathan, best known for her research on tuberculosis and HIV, was reported to have been served by the Indian Bar Association (IBA) for allegedly spreading disinformation in reference to the COVID-19 pandemic.


It is alleged Dr Swaminathan is being sued for misleading the Indian population by ignoring and suppressing information around the effectiveness of the drug Ivermectin in treating COVID-19, along with blocking its usage.


As a direct result of her advice not to use Ivermectin to cure COVID-19, cases exploded with deaths increasing ten-fold.

A health worker (pictured right) administers a COVID-19 vaccine at a Hospital in New Delhi, India in late January, 2021.

Additionally, a striking reduction in an unprecedented number of cases has transpired where Ivermectin was distrubuted, notably in the state of Uttar Pradesh, with further evidence outlining the benefits of Ivermectin use including Delhi, Uttarakhand, and Goa with COVID-19 cases declining sharply by as much as 98%, 97%, 94%, and 86%.


According to entries made by the Indian media, the notice is based on the research and clinical trials carried out by ‘Front Line COVID-19 Critical Care Alliance’ (FLCCC) and the UK group British Ivermectin Recommendation Development (BIRD).


Specific charges include Dr Swaminathan ignoring large amounts of clinical data showing Ivermectin's profound effectiveness in both the prevention and treatment of COVID-19, along with the doctor issuing incorrect statements to international, local media and social media platforms as an 'expert'.


The law suit further referenced peer-reviewed publications and evidence compiled by the ten-member Front Line COVID-19 Critical Care Alliance (FLCCC) group and the 65-member British Ivermectin Recommendation Development (BIRD) panel headed by WHO consultant and meta-analysis expert Dr. Tess Lawrie.

WHO clinical scientist Dr Soumya Swaminathan (pictured) is accused of ignoring clinical data showing Ivermectin's effectiveness in preventing and treating COVID-19 in India, killing thousands.


Indian Bar Association representative, Dipali Ojha, stated Dr Swaminathan is accused of misconduct after abusing her position as a public health official to maintain emergency use authorisation in order to ensure billions of dollars in profits for the vaccine industry.


The Association is taking action under section 302 of the Indian Penal Code to hold Dr Swaminathan responsible for the murder of each person who died due to her obstruction of treatment of COVID-19 patients with Ivermectin.


Any charges confirmed will be punishable by death or life imprisonment under the Indian Penal Code.


The allegations of misconduct place in doubt further recommendations made by Dr Swaminathan made in early May 2021 when she advised international health authorities the COVID-19 variant spreading in India was more contagious and was contributing to the country's explosive outbreak.


This statements made by Dr Swaminathan coincided with the commencement of India's vaccination rollout in late January 2021, with what was likely the world's largest COVID-19 vaccination campaign, the recipients including 30 million doctors, nurses and other front-line workers, followed by 270 million people who were either over 50 or who had illnesses that make them vulnerable to COVID-19.


Dr Swaminathan's 'expert' opinion on what was coined the 'B.1.617 variant' sent shockwaves around the world at the time after it was said to have been driving a huge wave in infections seen across India with advice stating India represented 50% of all COVID-19 cases and 30% of deaths from the virus globally.

A photograph reported to be of relatives consoling each other at a cremation in Jammu, India in April, 2021 after the rollout of the vaccine in early January, 2021.


As a result, the WHO designated the B.1.617 and its sublineages as a “variant of concern” classifying the variant to be more transmissible, and a more severe disease that had a failure to respond to treatments, evaded immune response and failed to be diagnosed by standard tests.


According to the WHO, the variantB.1.617 was consequently identified in 44 countries and on every continent, apart from Antarctica with the United Kingdom reported to be the largest number of cases of the strain outside India.


It was stated the United States — where B.1.617 was also present — the Centres for Disease Control and Prevention (CDC) also classified it as a “variant of interest,” yet noted that this classification could change, based on "scientific evidence".